WO2021050956A1 - Antiviral prodrugs and pharmaceutical compositions thereof - Google Patents

Antiviral prodrugs and pharmaceutical compositions thereof Download PDF

Info

Publication number
WO2021050956A1
WO2021050956A1 PCT/US2020/050511 US2020050511W WO2021050956A1 WO 2021050956 A1 WO2021050956 A1 WO 2021050956A1 US 2020050511 W US2020050511 W US 2020050511W WO 2021050956 A1 WO2021050956 A1 WO 2021050956A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
suspension
methyl
fluoro
purin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/050511
Other languages
English (en)
French (fr)
Inventor
Arnab Kumar CHATTERJEE
Anil Kumar Gupta
Andres Mikal ELIASEN
Sean Barry JOSEPH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US17/642,559 priority Critical patent/US12569510B2/en
Priority to CR20220110A priority patent/CR20220110A/es
Priority to IL327111A priority patent/IL327111A/en
Priority to CA3150418A priority patent/CA3150418A1/en
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Priority to PE2022000389A priority patent/PE20221037A1/es
Priority to PH1/2022/550527A priority patent/PH12022550527A1/en
Priority to AU2020346907A priority patent/AU2020346907B2/en
Priority to CR20260001A priority patent/CR20260001A/es
Priority to IL290919A priority patent/IL290919B2/en
Priority to KR1020227011982A priority patent/KR20220066303A/ko
Priority to CN202080077922.6A priority patent/CN114793421B/zh
Priority to NZ786018A priority patent/NZ786018B2/en
Priority to MX2022002899A priority patent/MX2022002899A/es
Priority to CN202411383875.4A priority patent/CN119462802A/zh
Priority to JP2022515857A priority patent/JP7719769B2/ja
Priority to EP20862704.2A priority patent/EP4028019A4/en
Priority to BR112022004417A priority patent/BR112022004417A2/pt
Publication of WO2021050956A1 publication Critical patent/WO2021050956A1/en
Priority to MX2025014404A priority patent/MX2025014404A/es
Priority to DO2022000055A priority patent/DOP2022000055A/es
Anticipated expiration legal-status Critical
Priority to CONC2022/0004681A priority patent/CO2022004681A2/es
Priority to US18/233,959 priority patent/US20230390318A1/en
Priority to IL320979A priority patent/IL320979B2/en
Priority to JP2025124956A priority patent/JP2025137788A/ja
Priority to AU2026204849A priority patent/AU2026204849A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Definitions

  • This invention relates to antiviral compounds and compositions useful for the treatment of acquired immunodeficiency syndrome (AIDS).
  • AIDS acquired immunodeficiency syndrome
  • EdA 4'-Ethynyl-2-fluoro-2'-deoxyadenosine
  • MK-8591 4'-Ethynyl-2-fluoro-2'-deoxyadenosine
  • Formula I is a nucleoside analog effective as an inhibitor of nucleoside reverse transcriptase (Current Opinion in HIV and AIDS 2018, 13, 294-299) and useful as an antiretroviral in the treatment and pre-exposure prophylaxis of a HIV- 1 infection.
  • EFdA is metabolized in cells to an active triphosphate anabolite (EFdA-TP), which inhibits HIV reverse transcriptase.
  • EFdA has a relatively high water solubility and relatively short time course of plasma concentration .
  • EFdA can provide only limited duration of viral suppression when administered to a patient for treatment of human immunodeficiency virus (HIV) infection, or for pre-exposure prophylaxis.
  • HIV human immunodeficiency virus
  • Antiviral compounds of the present invention are diesters of EFdA and have limited solubility in water. Whereas EFdA has an aqueous solubility of 0.877 mg/mL at physiological pH, the present diesters of EFdA have an aqueous solubility of less than 0.03 mg/mL at physiological pH, preferably less than 0 002 mg/mL. These diesters of EFdA are crystalline, are useful for providing an extended duration of suppression of HIV, and can be administered parenterally as a suspension in a pharmaceutically acceptable carrier.
  • a preferred prophylactic dose for a human subject is in the range of about 80 mg to about 800 mg of the EFdA diester administered parenterally at about six-month intervals in a dose volume of about 0 5 to about 4 milliliters per dose.
  • a preferred treatment dose for a human patient is in the range of about 80 mg to about 800 mg of the EFd A diester administered parenterally at about three-month intervals in a dose volume of about 0.5 to about 4 milliliters per dose
  • Parenteral formulations containing and antiviral compound of the present invention can be dry formulations comprising the antiviral compound together with pharmaceutically acceptabl e excipients or stable suspensions of the anti viral compound in an aqueous or oil- based medium.
  • Figure 1 shows an X-ray Powder Diffractogram (XPRD) of EFdA.
  • FIG. 2 shows data provided by Differential Scanning Calorimetry (DSC) and Thermo-Gravimetric Analysi s (TGA) of EFd A.
  • Figure 3 show's DSC and TGA data for Compound 2.
  • Figure 4 shows XPRD data for Compound 3.
  • Figure 5 shows DSC data for Compound 3.
  • FIG. 6 shows TGA data for Compound 3.
  • Figure 7 show's XPRD data for Compound 5.
  • Figure 8 show's DSC data for Compound 5.
  • Figure 9 shows TGA data for Compound 5.
  • Figure 10 shows in graphic form the data provided in Table 2.
  • Figure 11 show ' s in graphic form the data provided in Table 3.
  • Figure 12 shows in graphic form the data in Table 4.
  • Figure 13 shows in graphic form data from Example 10.
  • Figure 14 shows XPRD data for Compound 2.
  • Figure 15 show's XPRD data for Compound 6.
  • R 3 is a member of the group consisting of isopropyl, 3-pentyl, cyclopentyl and phenylmethyl.
  • Compound 2 was suspended in aqueous 0.25% CMC-Na/0.5% TWEEN-80 (26 gauge syringeability) and was subjected to stability for 2 weeks at
  • Figure 14 provides XPRD data for Compound 6 from the incubated suspension, prior to incubation (bottom plot), after one week (middle plot), and after two weeks (top plot), showing that the compound retains good crystallinity in suspension.
  • the reaction was monitored by LC-MS due to the occasional alkylation of NH 2 group observed for elongated reaction time.
  • the reaction mixture was quenched with methanol, and solvent was evaporated under reduced pressure.
  • the resulting crude material was purified by silica-gel column chromatography using 60-70% ethyl acetate (EtOAc) in hexanes to obtain Compound 3 as a glassy solid.
  • EtOAc ethyl acetate
  • the obtained glassy solid was dispersed in minimum amount of isopropanol followed by its rotatory evaporation to obtain pure Compound 3 as a white solid (1.33 g, 80% yield).
  • Compound 4 was prepared by using the procedure followed for the Compound 2 but using cyclopentanoic acid instead of isoutyric acid.
  • Table 1 presents compound characterization data obtained by nuclear magnetic resonance (NMR) and liquid chromatography-mass spectrometry (LC-MS).
  • NMR nuclear magnetic resonance
  • LC-MS liquid chromatography-mass spectrometry
  • Compound 6 was prepared by using the procedure similar to that used for Compound 2 using 4.5 equiv of corresponding acid.
  • About 275 mg/g of Compound 6 was suspended in aqueous 0.25% CMC-Na/0.5% TWEEN-80 (26 gauge syringeability) and was subjected to stability for 2 weeks at 40°C/75% relative humidity.
  • Figure 15 provides XPRD data for Compound 6 from the incubated suspension, prior to incubation (bottom plot), after one week (middle plot), and after two weeks (top plot), showing that the compound retains good crystallinity in suspension.
  • EFdA was ground and sieved through a #80 sieve.
  • a solution of preformed 0.25% sodium carboxymethyl cellulose (Sodium CMC) & 0.1% polyoxyethlene (20) sorbitan monooleate (TWEEN-80) was added to about 300 mg of EFdA (Compound 1) to provide a suspension of about 1 gram (300 mg of 1 + -700 mg of polymer solution) of the final formulation (about 300 mg/g).
  • the suspension was then bath sonicated for 10 min in an ice bath.
  • the density of formulation of was 1.064 g/mL and provided a 319.2 mg/mL concentration of EFdA.
  • Compound 3 was ground and sieved through No. 80 sieves U.S. Standard Sieve Series for Wire Cloth Screens (nominal sieve opening 0.180 mm).250 mg of Compound 3 was taken in suitable container and a solution of preformed 0.25% Sodium CMC and 0.5% TWEEN-80 was added to obtain 1 gram (250 mg of Compound 3 + -750 mg of polymer solution) of the final suspension ( ⁇ 250 mg/g). The suspension was then probe sonicated for 5 min in an ice bath (Sonication time: 5 min; Pulse Amplitude: 20; Pulse on Time: 30 sec; Pulse off time: 20 sec). The density of the suspension was of is 1.004 g/rnL. The above Suspension contained 250.88 mg/mL of Compound 3 (-150 mg/mL of EFdA).
  • Compound 5 was ground and sieved through No. 80 sieve U.S. Standard Sieve Series for Wire Cloth Screens (nominal sieve opening 0.180 mm). 200 mg of Compound 5 was placed in a suitable container and a solution of preformed 0.25% Sodium CMC and 0.5% TWEEN-80 was added to obtain 1 gram (200 mg of Compound 5 + ⁇ 800 mg of polymer solution) of the final suspension (-200 mg/g). The suspension was then probe sonicated for 5 min in an ice bath (Sonication time: 5 min; Pulse Amplitude: 20; Pulse on Time: 30 sec; Pulse off time: 20 sec). The density of the suspension was 1.047 g/mL. The above suspension contained 209.4 mg/mL of Compound 5 (-115.97 mg/mL of EFdA).
  • Animals Animals (Male SD rats -200-250 g and Male rhesus macaques ⁇ 2-3 kg) were obtained from an approved vendor (SLAC Laboratory Animal Co. Ltd., Shanghai, China and/or Topgene Biotechnology, Wuhan city, Hubei province, China).
  • Acclimation/Quarantine Following arrival, animals were assessed as to their general health by a member of the veterinary staff or other authorized personnel. Animals were acclimated for at least 3 days before being placed on study.
  • Animal Husbandry Animal s were group housed during acclimation and individually housed during the study. The animal room environment will be controlled (target conditions: temperature 18 to 26 °C, relative humidity 30 to 70%, 12 hours artificial light and 12 hours dark). Temperature and relative humidity were monitored daily.
  • SC Formulation Suspensions were prepared on the day of dosing according to the procedure described in Examples 2-5 above, and Tables 2-4. Animals were dosed within four hours of suspension preparation. TWO 20 mL aliquots of each prepared suspension were transferred into 1.5 mL of polypropylene microcentrifuge tubes and dose validation was run by LC/TJV or LC-MS/MS.
  • the suspensions were administered via subcutaneous injection (SC) following facility standard operations procedures (SOPs).
  • SC subcutaneous injection
  • SOPs facility standard operations procedures
  • Plasma samples were processed for plasma by centrifugation at approximately 4 °C, 3000 g 15 min within half an hour of collection. Plasma samples was stored in polypropylene tubes, quick frozen over dry ice and kept at -70+10 °C until LC/MS/MS analysis.
  • the concentration of the acti ve ingredient in each ali quot was determi ned by the LC/UV or LC/MS/MS method Bioanalytical method and sample analysis
  • the study sample analysis will be performed concurrently with a set of calibration standards and two sets of QC samples using the LC-MS/MS method (If sample numbers were more than 48, then two calibration curves with 2 sets of QC samples were applied).
  • the mean calculated concentration in the single blank matrix should be 0.5 times the LLQQ.
  • Sensitivity the LLOQ will target 1 ⁇ 3 ng/rnL.
  • Carryover the mean calculated carry-over concentration in the single blank matrix immediately after the highest standard injection should be LLQQ. If the carryover could’t meet the criteria, then the percent of carryover should be estimated following in-house bioanalytical SOP.
  • Plasma concentration versus time data was analyzed by non-compartmental approaches using the Phoenix WinNonlin 6.3 software program.
  • C max , T max , T 1 ⁇ 2 , AUC (0-t), AUC (0- ) , MRT (0-t) , MRT (0- ) , %F and graphs of plasma concentration versus time profile were generated.
  • prodrugs including EFdA (1) as a control were subjected to a single dose rat PK studies via subcutaneous route of administration. All animals were injected with equivalent doses of 10 mg/kg and concentration of 4 mg/mL of EFdA as an aqueous suspension in 0.5% CMC-Na and 0.5% TWEEN-80. While similar exposure was observed, all compounds 2, 3 and 5 exhibited plasma levels of EFdA above lower limit of quantitation (LLOQ) for more than a week with Cmax much lower than for EFdA.
  • LLOQ lower limit of quantitation
  • Table 2 shows the rat PK data for Compounds 1, 2, 3 and 5 following subcutaneous (SC) administration at 10 mg/kg equivalent dose of EFdA.
  • SC subcutaneous
  • Table 3 A and Table 3B show the rat PK data for Compounds 1, 3 and 5 following SC administration. The data for Compound 3 are shown in graphic form in Figure 11.
  • Table 3A SC Rat PK: EFdA Levels for EFdA and Compound 3
  • Table 3B SC Rat PK: EFdA Levels for EFdA and Compound 5
  • EXAMPLE 7 After rat PK analysis, the focus was shifted to non-rodents, i.e., rhesus macaque.
  • Compound 5 and EFdA were subjected to a single dose rhesus macaque PK studies via subcutaneous route of administration with equivalent doses of 50 mg/kg of EFdA.
  • the aqueous suspensions contained 0.25% CMC-Na and 0.1%/0.5% TWEEN-80 with equivalent concentration of 116 mg/mL and 319 mg/mL of EFdA for Compound 5 and EFdA respectively.
  • Compound 5 plasma levels of EFdA above LLOQ for more than a month with 24-fold lower C max than EFdA itself were observed.
  • Table 4 shows the Rhesus PK data for Compounds 1 and 5 following SC administration at 50 mg/kg equivalent dose of EFdA. The data are shown in graphic form in Figure 12.
  • Tabie 4 SC Rhesus PK: EFdA Plasma Leyels after Dosing EFdA or Compound 5 in Plasma
  • Suspending medium for the present compounds can be an aqueous vehicle such as water for injection (WFI) or a vegetable oil vehicle such as sesame oil, olive oil, and the like.
  • the suspending medium can also contain pharmaceutically acceptable excipients such as non-ionic surfactant, suspending or flocculating agent, preservatives, buffers, toxicity adjusters, chelating agents, antioxidants, and the like.
  • a preferred prophylactic dose for a human subject is in the range of about 80 mg to about 800 mg of the antiviral compound administered parenterally at about six-month (semi-annual) intervals in a dose volume of about 0.5 to about 4 milliliters (rnL) per dose.
  • the effective amount of the antiviral compound of this invention preferably ranges from about 80 mg to about 800 mg at a dose volume of about 0.5 to about 4 mL per dose, more preferably an effective amount in the range of about 200 to about 400 mg, for a three-month dosage regimen.
  • the dosage regimen can vary', however, depending on the time interval between administered doses in a particular dosing regimen.
  • an amount of the antiviral compound means an amount of the antiviral compound sufficient to inhibit HIV reverse transcriptase, inhibit HIV replication, exert a prophylactic effect and/or exert a therapeutic effect after administration.
  • administration and variants thereof, for example “administering a compound”, with reference to the claimed method of treatment means providing the antiviral compound to the patient and includes self-administration as well as administration to the patient by another person.
  • the parenteral suspensions suitable for injection contain the present antiviral compound in an amount in the range of about 3 to 45 percent by weight, based on the weight of the suspension.
  • Preferred particle size is no greater than about 50 micrometers ( mm), more preferably an average particle size in the range of about 6 mm to about 15 mm.
  • Preferred flocculating or suspending agents are linear polymers, particularly the substituted celluloses such as methyl cellulose, carboxymethyl cellulose (CMC), hyroxypropyl cellulose, hydroxypropylmethyl cellulose, and the like.
  • Preferred surfactants are non-ionic surfactants.
  • Particularly preferred surfactant is polyoxyethlene (20) sorbitan monooleate (TWEEN-80).
  • the present compounds can also be administered in oral dosage forms and as implants.
  • Dosage forms containing the present compounds can also include additional anti- HIV and/or anti-HBV agents such as cabotegravir, dolutegravir, doravirine, evilegravir, lesiverine, tenofovir disoproxil fumarate, tenofovir alafenamide fumarate, lamivudine, and the like.
  • additional anti- HIV and/or anti-HBV agents such as cabotegravir, dolutegravir, doravirine, evilegravir, lesiverine, tenofovir disoproxil fumarate, tenofovir alafenamide fumarate, lamivudine, and the like.
  • the invention further provides, in various embodiments, a method of prophylaxis of viremia or treatment of a viral infection in a patient wherein inhibition of a reverse transcriptase is medically indicated, comprising administering to the patient an effective amount or concentration of a compound of Formula (II).
  • the compound of Formula (II) can be administered in a formulation that provides for slow or controlled or sustained release of EFdA from these prodrugs.
  • the compound of Formula (II) can be formulated as aqueous suspension, solutions, and can be encapsulated in particles for slow-release including PLGA and other such materials known in the art.
  • the viral infection can be caused by HIV or HBV.
  • the routes of administration for these prodrugs can include, but not limited to, oral, parenteral and release from implants (drug delivery composition and device).
  • the method may further comprise an additional anti -HIV and/or anti -HBV agent including but not limited to, cabotegravir, dolutegravir, doravirine, elvitegravir, lersiverine, tenofovir disoproxil fumarate, tenofovir alafenamide fumarate, lamivudine, and the like.
  • EXAMPLE 8 The concentration of surfactant was optimized with 0.3% and 0.5% of methyl cellulose in a formation containing 400 mg/gm of micronized Compound 5. Formulations were prepared with different concentrations of TWEEN-80 (0.1, 0.2 and 0.3%). No significant effect of surfactant concentration was observed in viscosity, flow and redispersion time in the formulations after 10 days of storage. The observations are reported in Table 5.
  • Tabie 5 Optimization of Surfactant Concentration with 400 mg/gm of Componnd 5
  • Viscosity ++++ Slightly Viscous, +++ Viscous, ++ Very Viscous, + Semisolid
  • a bulk batch (40 gm) of Compound 5 suspension was prepared with 0.3% methyl cellulose and 0.2% TWEEN-80 concentration. Although the polymer and surfactant concentrations were optimized with 40 weight % of drug concentration, a bulk batch was also prepared with 35 weight % of drug concentration during accelerated and long term stability studies.
  • the composition of formulation loaded in stability chamber is given in Table 6. A detailed manufacturing procedure of formulation preparation and composition is given below.
  • Methyl cellulose was slowly added to the requisite quantity of water for injection (WFI) in a glass bottle with continuous stirring. The resulting mixture was stirred until the solution was clear and free from any lumps using a magnetic stirrer. TWEEN-80 (0.08 g) was added to the obtained solution and stirred well.
  • WFI water for injection
  • Micronized Compound 5 (14 g; average particle size 11 mm) was slowly added to the prepared polymer, surfactant solution under vigorous stirring at 1400 rpm using a magnetic stirrer. After complete addition of Compound 5, the obtained suspension was stirred (600 rmm) for 20 minutes to uniformly disperse the particles.
  • the prepared formulation was characterized for various physicochemical properties such as assay, pH, % purity, redispersability, injectability, polymorphic form and particle size. The results are presented in Table 7.
  • Tabie 7 Physicochemical Characterization of Formulation on Preparation
  • Aqueous suspensions of EFdA and of Compounds 3 and 5 were administered subcutaneously to Rhesus Macaque, peripheral blood mononuclear cells (PBMC) periodically retrieved, and pharmaconkinetic data evaluated.
  • PBMC peripheral blood mononuclear cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PCT/US2020/050511 2019-09-11 2020-09-11 Antiviral prodrugs and pharmaceutical compositions thereof Ceased WO2021050956A1 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
NZ786018A NZ786018B2 (en) 2020-09-11 Antiviral prodrugs and pharmaceutical compositions thereof
IL327111A IL327111A (en) 2019-09-11 2020-09-11 Antiviral prodrugs and their pharmaceutical preparations
CA3150418A CA3150418A1 (en) 2019-09-11 2020-09-11 ANTIVIRAL PRODRUGS AND RELATED PHARMACEUTICAL COMPOSITIONS
CN202411383875.4A CN119462802A (zh) 2019-09-11 2020-09-11 抗病毒前体药物及其药物组合物
PE2022000389A PE20221037A1 (es) 2019-09-11 2020-09-11 Profarmacos antivirales y composiciones farmaceuticas de los mismos
PH1/2022/550527A PH12022550527A1 (en) 2019-09-11 2020-09-11 Antiviral prodrugs and pharmaceutical compositions thereof
AU2020346907A AU2020346907B2 (en) 2019-09-11 2020-09-11 Antiviral prodrugs and pharmaceutical compositions thereof
CR20260001A CR20260001A (es) 2019-09-11 2020-09-11 Profármacos antivirales y composiciones farmacéuticas de los mismos (divisional expediente 2022-0110)
CR20220110A CR20220110A (es) 2019-09-11 2020-09-11 Profármacos antivirales y composiciones farmacéuticas de los mismos
KR1020227011982A KR20220066303A (ko) 2019-09-11 2020-09-11 항바이러스 전구약물 및 이의 약제학적 조성물
CN202080077922.6A CN114793421B (zh) 2019-09-11 2020-09-11 抗病毒前体药物及其药物组合物
MX2022002899A MX2022002899A (es) 2019-09-11 2020-09-11 Profarmacos antivirales y composiciones farmaceuticas de los mismos.
IL290919A IL290919B2 (en) 2019-09-11 2020-09-11 Antiviral prodrugs and their pharmaceutical preparations
US17/642,559 US12569510B2 (en) 2019-09-11 2020-09-11 Antiviral prodrugs and pharmaceutical compositions thereof
JP2022515857A JP7719769B2 (ja) 2019-09-11 2020-09-11 抗ウイルスプロドラッグ及びその医薬組成物
EP20862704.2A EP4028019A4 (en) 2019-09-11 2020-09-11 ANTIVIRAL PRODRUGS AND PHARMACEUTICAL COMPOSITIONS THEREOF
BR112022004417A BR112022004417A2 (pt) 2019-09-11 2020-09-11 Pró-fármacos antivirais e composições farmacêuticas dos mesmos
MX2025014404A MX2025014404A (es) 2019-09-11 2022-03-09 Profarmacos antivirales y composiciones farmaceuticas de los mismos
DO2022000055A DOP2022000055A (es) 2019-09-11 2022-03-10 Profármacos antivirales y composiciones farmacéuticas de los mismos
CONC2022/0004681A CO2022004681A2 (es) 2019-09-11 2022-06-22 Profármacos antivirales y composiciones farmacéuticas de los mismos
US18/233,959 US20230390318A1 (en) 2019-09-11 2023-08-15 Antiviral Prodrugs and Pharmaceutical Compositions Thereof
IL320979A IL320979B2 (en) 2019-09-11 2025-05-18 Antiviral prodrugs and their pharmaceutical preparations
JP2025124956A JP2025137788A (ja) 2019-09-11 2025-07-25 抗ウイルスプロドラッグ及びその医薬組成物
AU2026204849A AU2026204849A1 (en) 2019-09-11 2026-06-23 Antiviral prodrugs and pharmaceutical compositions thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962898679P 2019-09-11 2019-09-11
US62/898,679 2019-09-11

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US17/642,559 A-371-Of-International US12569510B2 (en) 2019-09-11 2020-09-11 Antiviral prodrugs and pharmaceutical compositions thereof
US18/233,959 Continuation US20230390318A1 (en) 2019-09-11 2023-08-15 Antiviral Prodrugs and Pharmaceutical Compositions Thereof

Publications (1)

Publication Number Publication Date
WO2021050956A1 true WO2021050956A1 (en) 2021-03-18

Family

ID=74866690

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2020/050511 Ceased WO2021050956A1 (en) 2019-09-11 2020-09-11 Antiviral prodrugs and pharmaceutical compositions thereof
PCT/US2020/050519 Ceased WO2021050961A1 (en) 2019-09-11 2020-09-11 Antiviral prodrugs and formulations thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2020/050519 Ceased WO2021050961A1 (en) 2019-09-11 2020-09-11 Antiviral prodrugs and formulations thereof

Country Status (18)

Country Link
US (3) US20220323476A1 (cg-RX-API-DMAC7.html)
EP (2) EP4028019A4 (cg-RX-API-DMAC7.html)
JP (4) JP7703518B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220066303A (cg-RX-API-DMAC7.html)
CN (4) CN119462802A (cg-RX-API-DMAC7.html)
AU (4) AU2020346907B2 (cg-RX-API-DMAC7.html)
BR (2) BR112022004424A2 (cg-RX-API-DMAC7.html)
CA (2) CA3150467A1 (cg-RX-API-DMAC7.html)
CL (4) CL2022000587A1 (cg-RX-API-DMAC7.html)
CO (2) CO2022005128A2 (cg-RX-API-DMAC7.html)
CR (3) CR20260001A (cg-RX-API-DMAC7.html)
DO (2) DOP2022000055A (cg-RX-API-DMAC7.html)
IL (5) IL319709A (cg-RX-API-DMAC7.html)
MX (4) MX2022002897A (cg-RX-API-DMAC7.html)
PE (2) PE20221037A1 (cg-RX-API-DMAC7.html)
PH (2) PH12022550528A1 (cg-RX-API-DMAC7.html)
UA (1) UA130229C2 (cg-RX-API-DMAC7.html)
WO (2) WO2021050956A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023518433A (ja) * 2020-03-20 2023-05-01 ギリアード サイエンシーズ, インコーポレイテッド 4’-c-置換-2-ハロ-2’-デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
WO2025006586A1 (en) 2023-06-27 2025-01-02 Gilead Sciences, Inc. Solid forms of a nucleoside reverse transcriptase translocation inhibitor
US12569510B2 (en) 2019-09-11 2026-03-10 The Scripps Research Institute Antiviral prodrugs and pharmaceutical compositions thereof

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
IL289925B2 (en) 2019-07-27 2026-03-01 Brii Biosciences Inc A derivative of adenosine and a pharmaceutical preparation containing it
IL293566A (en) * 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
KR20220132608A (ko) 2020-01-27 2022-09-30 길리애드 사이언시즈, 인코포레이티드 SARS CoV-2 감염증을 치료하기 위한 방법
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
JP7482250B2 (ja) 2020-04-06 2024-05-13 ギリアード サイエンシーズ, インコーポレイテッド 1’-シアノ置換カルバヌクレオシド類似体の吸入製剤
EP4157272B1 (en) 2020-05-29 2025-07-02 Gilead Sciences, Inc. Remdesivir for the treatment of viral infections
IL299202A (en) 2020-06-24 2023-02-01 Gilead Sciences Inc 1'-cyano nucleoside analogs and uses thereof
US11926645B2 (en) 2020-08-27 2024-03-12 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
AU2022211056A1 (en) 2021-01-25 2023-07-20 Brii Biosciences, Inc. Combination therapy for hiv with adenosine derivative and capsid inhibitors
KR20230132476A (ko) 2021-01-25 2023-09-15 브리 바이오사이언시스, 인크. 아데노신 유도체 및 이를 포함하는 약제학적 조성물
US20240190878A1 (en) * 2021-03-16 2024-06-13 The Scripps Research Institute Antiviral prodrugs of etv and formulations thereof
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
EP4547665A1 (en) 2022-06-30 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
TW202500140A (zh) * 2023-06-27 2025-01-01 美商基利科學股份有限公司 製備抗病毒前藥之方法及中間物
FI132042B1 (en) 2024-01-17 2026-05-04 Metso Finland Oy Precipitation of calcium compounds in liquid extraction systems

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7339053B2 (en) * 2004-03-24 2008-03-04 Yamasa Corporation 4′-C-substituted-2-haloadenosine derivative
US8835615B2 (en) * 2007-07-16 2014-09-16 Junbiao Chang 2′-fluorine-4′-substituted-nucleoside analogues, preparation methods and uses thereof
WO2017053216A2 (en) 2015-09-23 2017-03-30 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
US20180002366A1 (en) * 2014-03-28 2018-01-04 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
WO2019113462A1 (en) 2017-12-07 2019-06-13 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283067A (en) 1987-01-30 1994-02-01 Ciba-Geigy Corporation Parenteral suspensions
US5192749A (en) 1990-05-21 1993-03-09 Syntex (U.S.A.) Inc. 4'-substituted nucleosides
FR2694693B1 (fr) 1992-07-28 1994-10-28 Abrax Bio Labs Sa Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH.
DE60005502T2 (de) 1999-05-12 2004-06-24 Yamasa Corp., Choshi 4'-c-ethynyl-purin-nukleoside
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
EA200800932A1 (ru) 2005-09-26 2008-10-30 Фармассет, Инк. Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
US20090274686A1 (en) * 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
MX2011006890A (es) 2008-12-23 2011-07-20 Pharmasset Inc Analogos de nucleosidos.
US20130244966A1 (en) 2011-12-12 2013-09-19 Catabasis Pharmaceuticals, Inc. Fatty acid antiviral conjugates and their uses
FI3265102T3 (fi) 2015-03-06 2025-10-31 Atea Pharmaceuticals Inc Beta-d-2'-deoksi-2'-alfa-fluori-2'-beta-c-substituoituja-2-modifioituja-n6-substituoituja puriininukleotideja hcv-hoitoa varten
WO2017100108A1 (en) * 2015-12-10 2017-06-15 Merck Sharp & Dohme Corp. Antiviral phosphodiamide prodrugs of tenofovir
FR3053281B1 (fr) 2016-06-30 2020-03-27 Banque De France Procede de fabrication d'un document de securite presentant un signe de securite a contraste de brillance
US10185393B2 (en) 2017-04-03 2019-01-22 Facebook Technologies, Llc Waveguide display with spatially switchable grating
US20190185508A1 (en) 2017-12-15 2019-06-20 Merck Sharp & Dohme Corp. Deuterated nucleoside reverse transcriptase inhibitors
WO2019171285A1 (en) * 2018-03-07 2019-09-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
MA53280A (fr) 2018-08-09 2021-11-17 Glaxosmithkline Ip No 2 Ltd Composés utiles dans la thérapie du vih
US11572595B2 (en) * 2018-12-31 2023-02-07 Roche Molecular Systems, Inc. Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
PH12021500034A1 (en) 2019-03-06 2022-06-06 Glaxosmithkline Ip No 2 Ltd Compounds useful in hiv therapy
IL289925B2 (en) 2019-07-27 2026-03-01 Brii Biosciences Inc A derivative of adenosine and a pharmaceutical preparation containing it
MX2022002897A (es) 2019-09-11 2022-05-16 Scripps Research Inst Profarmacos antivirales y formulaciones de los mismos.
CN121358747A (zh) 2023-06-27 2026-01-16 吉利德科学公司 核苷逆转录酶易位抑制剂的固体形式
TW202500140A (zh) 2023-06-27 2025-01-01 美商基利科學股份有限公司 製備抗病毒前藥之方法及中間物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7339053B2 (en) * 2004-03-24 2008-03-04 Yamasa Corporation 4′-C-substituted-2-haloadenosine derivative
US8835615B2 (en) * 2007-07-16 2014-09-16 Junbiao Chang 2′-fluorine-4′-substituted-nucleoside analogues, preparation methods and uses thereof
US20180002366A1 (en) * 2014-03-28 2018-01-04 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
WO2017053216A2 (en) 2015-09-23 2017-03-30 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
WO2019113462A1 (en) 2017-12-07 2019-06-13 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CURRENT OPINION IN HIV AND AIDS, vol. 13, 2018, pages 294 - 299
KAGEYAMA ET AL.: "Enantioselective Total Synthesis of the Potent Anti-HIV Nucleoside EFdA", ORGANIC LETTERS, vol. 13, no. 19, 2 September 2011 (2011-09-02), pages 5264 - 5266, XP055582151, DOI: 10.1021/ol202116k *
See also references of EP4028019A4

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12569510B2 (en) 2019-09-11 2026-03-10 The Scripps Research Institute Antiviral prodrugs and pharmaceutical compositions thereof
JP2023518433A (ja) * 2020-03-20 2023-05-01 ギリアード サイエンシーズ, インコーポレイテッド 4’-c-置換-2-ハロ-2’-デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
US11718637B2 (en) 2020-03-20 2023-08-08 Gilead Sciences, Inc. Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same
WO2025006586A1 (en) 2023-06-27 2025-01-02 Gilead Sciences, Inc. Solid forms of a nucleoside reverse transcriptase translocation inhibitor

Also Published As

Publication number Publication date
JP2025137788A (ja) 2025-09-19
IL320979A (en) 2025-07-01
IL290861A (en) 2022-04-01
JP7719769B2 (ja) 2025-08-06
EP4028020A1 (en) 2022-07-20
CA3150467A1 (en) 2021-03-18
CR20220110A (es) 2022-06-16
MX2022002897A (es) 2022-05-16
PE20221036A1 (es) 2022-06-17
NZ786022A (en) 2025-05-30
MX2025011432A (es) 2025-11-03
CN118580291A (zh) 2024-09-03
BR112022004424A2 (pt) 2022-05-31
EP4028019A1 (en) 2022-07-20
AU2020346908B2 (en) 2026-02-12
NZ786018A (en) 2025-05-30
CR20220109A (es) 2022-06-07
US20220332751A1 (en) 2022-10-20
CL2022000601A1 (es) 2022-10-28
IL320979B1 (en) 2026-04-01
IL290919B2 (en) 2025-10-01
PH12022550527A1 (en) 2023-09-04
MX2025014404A (es) 2026-01-07
US12569510B2 (en) 2026-03-10
CA3150418A1 (en) 2021-03-18
PH12022550528A1 (en) 2023-09-04
PE20221037A1 (es) 2022-06-17
IL290919B1 (en) 2025-06-01
US20220323476A1 (en) 2022-10-13
KR20220066303A (ko) 2022-05-24
CO2022005128A2 (es) 2022-05-10
IL290919A (en) 2022-04-01
CN114929236B (zh) 2024-06-07
EP4028020A4 (en) 2023-09-27
IL290861B1 (en) 2025-04-01
WO2021050961A1 (en) 2021-03-18
MX2022002899A (es) 2022-05-16
AU2020346907A1 (en) 2022-03-24
AU2026204849A1 (en) 2026-07-09
IL327111A (en) 2026-05-01
CN114793421B (zh) 2024-09-13
CL2022000587A1 (es) 2022-10-28
DOP2022000055A (es) 2022-06-15
CN119462802A (zh) 2025-02-18
IL319709A (en) 2025-05-01
AU2020346907A2 (en) 2022-06-16
CN114929236A (zh) 2022-08-19
JP2025096427A (ja) 2025-06-26
EP4028019A4 (en) 2024-04-17
CN114793421A (zh) 2022-07-26
AU2026203582A1 (en) 2026-05-28
CR20260001A (es) 2026-04-12
CO2022004681A2 (es) 2022-07-19
DOP2022000056A (es) 2022-06-15
KR20220066302A (ko) 2022-05-24
IL290861B2 (en) 2025-08-01
IL320979B2 (en) 2026-08-01
UA130229C2 (uk) 2025-12-24
BR112022004417A2 (pt) 2022-06-21
AU2020346908A2 (en) 2022-06-16
CL2024003241A1 (es) 2025-01-03
AU2020346908A1 (en) 2022-03-24
JP2022547978A (ja) 2022-11-16
AU2020346907B2 (en) 2026-07-16
JP7703518B2 (ja) 2025-07-07
CL2025003801A1 (es) 2026-03-27
JP2022547558A (ja) 2022-11-14
US20230390318A1 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
US20230390318A1 (en) Antiviral Prodrugs and Pharmaceutical Compositions Thereof
EA028026B1 (ru) Противовирусное соединение, содержащая его фармацевтическая композиция и способ лечения
EA012701B1 (ru) Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы
US10253031B2 (en) Stable pemetrexed arginine salt and compositions comprising it
WO2020196814A1 (en) Benzoazepine compound-containing freeze-dried composition
US6936596B2 (en) Adenosine derivatives and use thereof
EP0359148A1 (en) Benzoyl urea compound-albumin complex
AU739673B2 (en) Lyophilized compositions containing sphingoglycolipid and process for preparing them
US8349811B2 (en) Stable 6-methoxy-2′,3′-dideoxyguanosine, method for preparing the same and pharmaceutical composition containing the same
KR102788736B1 (ko) 16α-브로모-3β-히드록시-5α-안드로스탄-17-케톤 및 이의 수화물, 유도체 및 유사체를 포함하는 수성 현탁액 조성물, 제제 및 수분산 건조 조성물
HK40076147A (en) Antiviral prodrugs and pharmaceutical compositions thereof
EA049868B1 (ru) Противовирусные пролекарства и их фармацевтические композиции
JPH0643437B2 (ja) レベカマイシン類似体の安定な溶液およびその製造
HK40123101A (en) Antiviral prodrugs and pharmaceutical compositions thereof
EP0006639A1 (en) Crystalline N-formimidoyl thienamycin
HU199289B (en) Process for production of liofilized medical compositions containing derivatives of phenil-quinoline-carbonic acid
US20160095925A1 (en) Stable formulation of azacitidine or salts thereof and their process for preparation
EA053005B1 (ru) Противовирусные пролекарства и их фармацевтические композиции
HK40076147B (en) Antiviral prodrugs and pharmaceutical compositions thereof
US7504415B2 (en) Therapeutic agent for glomerular disease
EP2303228B1 (en) Fosphenytoin composition
US20200206129A1 (en) Formulations for intravenous administration
US20150174097A1 (en) Treating ewing's sarcoma and ews-fli1 related disorders
US20240180935A1 (en) Solution formulation of cyclophosphamide
EA045403B1 (ru) Лиофилизированная композиция, содержащая соединение бензоазепина

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20862704

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 290919

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 3150418

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2022/002899

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2022515857

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022004417

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2020346907

Country of ref document: AU

Date of ref document: 20200911

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20227011982

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020862704

Country of ref document: EP

Effective date: 20220411

ENP Entry into the national phase

Ref document number: 112022004417

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220310

WWE Wipo information: entry into national phase

Ref document number: NC2022/0004681

Country of ref document: CO

WWP Wipo information: published in national office

Ref document number: NC2022/0004681

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 522431901

Country of ref document: SA

WWE Wipo information: entry into national phase

Ref document number: 524462259

Country of ref document: SA

WWG Wipo information: grant in national office

Ref document number: 202247020416

Country of ref document: IN

WWD Wipo information: divisional of initial pct application

Ref document number: 320979

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 524462259

Country of ref document: SA

WWG Wipo information: grant in national office

Ref document number: 786018

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 524462259

Country of ref document: SA

WWE Wipo information: entry into national phase

Ref document number: CR2026-000001

Country of ref document: CR

WWG Wipo information: grant in national office

Ref document number: MX/A/2022/002899

Country of ref document: MX

WWG Wipo information: grant in national office

Ref document number: 17642559

Country of ref document: US

WWD Wipo information: divisional of initial pct application

Ref document number: 327111

Country of ref document: IL

WWP Wipo information: published in national office

Ref document number: 327111

Country of ref document: IL

WWP Wipo information: published in national office

Ref document number: CR2026-000001

Country of ref document: CR

WWG Wipo information: grant in national office

Ref document number: 320979

Country of ref document: IL